shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.
By comparison, Pfizer has said it expects Covid vaccine sales of $36 billion this year and $29 billion in 2022. He said the company is working to ensure the vaccine is available in low-income countries by providing approximately 10% of its 2021 volume to them, and "significantly more" volume next year.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: